Andrographolide, a natural anti-inflammatory agent: An Update

Botanicals have attracted much attention in the field of anti-inflammatory due to their good pharmacological activity and efficacy. Andrographis paniculata is a natural plant ingredient that is widely used around the world. Andrographolide is the main active ingredient derived from Andrographis pani...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 13; p. 920435
Main Authors Li, Xiaohong, Yuan, Weichen, Wu, Jibiao, Zhen, Jianhua, Sun, Qihui, Yu, Minmin
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 27.09.2022
Subjects
andrographolide
anti-inflammation
immunomodulation
inflammatory diseases
Pharmacology
review
Online AccessGet full text

Cover

More Information
Summary:Botanicals have attracted much attention in the field of anti-inflammatory due to their good pharmacological activity and efficacy. Andrographis paniculata is a natural plant ingredient that is widely used around the world. Andrographolide is the main active ingredient derived from Andrographis paniculata , which has a good effect on the treatment of inflammatory diseases. This article reviews the application, anti-inflammatory mechanism and molecular targets of andrographolide in different inflammatory diseases, including respiratory, digestive, immune, nervous, cardiovascular, skeletal, and tumor system diseases. And describe its toxicity and explain its safety. Studies have shown that andrographolide can be used to treat inflammatory lesions of various systemic diseases. In particular, it acts on many inflammation-related signalling pathways. The future direction of andrographolide research is also introduced, as is the recent research that indicates its potential clinical application as an anti-inflammatory agent.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Wan Shun Daniel Tan, The University of Melbourne, Australia
Edited by: Günther Weindl, University of Bonn, Germany
These authors have contributed equally to this work and share first authorship
Reviewed by: Arjun Singh, Memorial Sloan Kettering Cancer Center, United States
This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.920435